Reports / Specific Analyses

Dear colleagues,

The 1996-2019 update of the Nationwide Registry for Childhood Hematological Malignancies (NARECHEM-ST, www.narechem.gr) in Greece is available. Updated fully anonmymized data have been also contributed to the IARC related European Pediatric Cancer Registries (ACCIS, CI5-X CI5plus, EUROCIM και EUROCAR). Interested scientists can address a request to be reviewed by E. Petridou and E. Ntzani.

Reports

Childhood leukemia in Greece (1996-2019): ACUTE LEUKEMIA (ALL & AML)
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
· Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender
· Incidence Rates per 1,000,000 by age group and gender
· Incidence Rates per 1,000,000 by age group and histological subtype

Childhood lymphoma in Greece (1996-2019): LYMPHOMA (HL and NHL)
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype
· Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender
· Incidence Rates per 1,000,000 by age group and histological subtype
· Incidence Rates per 1,000,000 by age group and gender

Childhood central nervous system (CNS) tumors (2010-2019)
· Incidence Rates per 1,000,000 by age group and histological subtype
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Number of cases by behavior
· Incidence Rates per 1,000,000 by age group and gender
· Age-Standardized Incidence Rates (AIR) per 1,000,000 by behavior and gender
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by behavior
· Number of cases by ICCC-3 group III histological subtype
· Number of cases by histological subtype
· Incidence Rates per 1,000,000 by age group and ICCC-3 group III histological subtype
· Incidence Rates per 1,000,000 by age group and histological subtype
· Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender and ICCC-3 group III histological subtype
· Age-Standardized Incidence Rates (AIR) per 1,000,000 by histological subtype and gender

Childhood Neuroblastomas in Greece (2009-2019)
· Percentage of cases by stage of INRG
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Incidence Rates per 1,000,000 by age group and gender
· Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender

Childhood Wilm’s Tumors (Nephroblastomas) in Greece (2009-2019)
· Percentage of cases by anatomical stage
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Incidence Rates per 1,000,000 by age group and gender
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Incidence Rates per 1,000,000 by age group and gender
· Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender

Childhood Liver Tumors in Greece (2001-2019)
· Annual Crude and Age-Standardized Incidence Rates per 1,000,000
· Annual Age-Standardized Incidence Rates (AIR) per 1,000,000 by gender
· Annual Crude Incidence Rates (CIR) per 1,000,000 by age group
· Incidence Rates per 1,000,000 by age group and gender

NARECHEM-ST: descriptive data at a glance

Time trends (1996-2019) of childhood leukemias in Greece reach the statistically significant increase observed in other developed countries only in the crude incidence rate and merely so in age standardized rate curve
ALL and AML leukemia subtypes both contribute to the annual incidence increase, though the trend does not reach statistical significance in either of them, possibly due to small numbers
Gender and age patterns are in line with literature, Specifically, boys outnumber girls (male/female incidence rate ratio: 1.18) on account of ALL preponderance (male/female incidence rate ratio: 1.23); of note, the gender ratio for AML is 0.85
The peak age distribution for ALL is 1-4 years, whereas AML is more prevalent among less than two years infants and adolescents.
Time trends (1996-2019) show no increase, but rather reflect the expected fluctuations during the study period. Non Hodgkin cases outnumber Hodgkin lymphomas (1.35), whereas Burkitt Non Hodgkin lymphomas comprise 46% of total Burkitt lymphomas
Overall, boys outnumber girls by 2.3; the gender ratio is 3:1 for Non Hodgkin and 3:2 for Hodgkin lymphoma
Lymphomas are rare in early childhood (0-4 years:14.2%); their proportion increases to 33.1% among children 5-9 years and peaks among those 10-14 year of age (52.7%)
Time trends (2010-2019) of CNS tumors during the study period remain relatively constant. Of the total CNS tumors cases, 59% had malignant behavior. Incidence rates of CNS tumors seem to decrease by advancement of age group.
The majority of CNS tumors were astrocytomas (37%), followed by embryonal tumors (22%), ependynomas (10%) and other giliomas (9%).
Time trends of Wilm’s tumors (2009-2019) showed a 4.23% non-significant decrease (95% CI: -9.33%, 1.16%)
The majority of Wilm’s tumors (86.5%) presented as anatomical stage I-III, whereas the incidence rates peaked in the age group 1-4 years.
Time trends of neuroblastomas (2009-2019) showed a 2.42% non-significant decrease (95% CI: -6.47%, 1.79%). Incidence rates were higher during the first year of life and higher for boys vs. girls
Based on the INRG stages, most neuroblastomas were L1 stage (33.5%) followed by M stage (32%).
During the study period (2001-2019) no significant time trend was observed for liver tumors
The vast majority of cases were observed during the first year of life, although the rates seem to increase for the age group of 1-4 years.

NARECHEM-ST - Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors

Navigation

Reports / Specific Analyses

Reports

NARECHEM-ST: descriptive data at a glance